{"id":35334,"date":"2024-04-02T13:15:55","date_gmt":"2024-04-02T11:15:55","guid":{"rendered":"https:\/\/www.abcsg.org\/?page_id=35334"},"modified":"2026-08-11T16:04:46","modified_gmt":"2026-08-11T14:04:46","slug":"abcsg-62-cambria-2-2","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/abcsg-studien\/studies-in-treatment-phase-follow-up\/abcsg-62-cambria-2-2\/","title":{"rendered":"ABCSG 62 \/ CAMBRIA-2"},"content":{"rendered":"<p>A phase III, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or Tamoxifen) as adjuvant treatment for patients with ER-positive\/HER2- negative early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease.<\/p>\n<table class=\"studienmeta-public\">\n<tbody>\n<tr>\n<td><strong>Studienstart:<\/strong><\/td>\n<td>(global): 10\/2023; FPI 10\/2023<br \/>\n(national): 04\/2024<\/td>\n<\/tr>\n<tr>\n<td><strong>Coordinating Investigator AT:<\/strong><\/td>\n<td>Daniel Egle, Innsbruck<\/td>\n<\/tr>\n<tr>\n<td><strong>Stichprobenumfang:<\/strong><\/td>\n<td>5500 (global),<br \/>\n128 (national)<\/td>\n<\/tr>\n<tr>\n<td><strong>Sponsor:<\/strong><\/td>\n<td>AstraZeneca<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><strong>Description and status:<\/strong><\/h3>\n<p>The phase III global open label trial ABCSG 62 \/ CAMBRIA-2 is assessing the efficacy and safety of camizestrant (+\/- abemaciclib) versus standard endocrine therapy (+\/- abemaciclib) as adjuvant treatment for patients with ER-positive\/HER2-negative early breast cancer and an intermediate- high or high risk of recurrence, who have completed definitive locoregional treatment and have no evidence of disease.<\/p>\n<p>The CAMBRIA-2 trial is aiming to demonstrate superiority of camizestrant with or without abemaciclib as compared to standard endocrine therapy (ET) with or without abemaciclib by assessment of invasive breast cancer-free survival (IBCFS) as its primary objective. Patients receive 75 mg camizestrant daily, or standard endocrine therapy, for a period of 7 years. A subset of patients \u2013 as clinically indicated \u2013 will also receive abemaciclib for the first 2 years of treatment, although this proportion is capped at max. 30% of the study population.<\/p>\n<p>Due to the outstanding global enrollment numbers, the recruitment phase ended significantly earlier than originally planned; recruitment concluded on July 1, 2026, with a total of 5,511 patients enrolled. A total of 100 patients were enrolled in the study at 15 participating study sites in Austria. The treatment and follow-up phase of the CAMBRIA-2 study will focus on the treatment and documentation of the participating patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A phase III, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or Tamoxifen) as adjuvant treatment for patients with ER-positive\/HER2- negative early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":32914,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-onepagestudy.php","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"tags":[],"class_list":["post-35334","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2027-02-11 17:10:28","action":"delete","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=35334"}],"version-history":[{"count":4,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35334\/revisions"}],"predecessor-version":[{"id":42015,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35334\/revisions\/42015"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/32914"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=35334"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=35334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}